- ISIN
- IE00B56GVS15
- CUSIP
- 00B56GVS1
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 16, 1991
Highlights
- Market Cap
- $7.99B
- Enterprise Value
- $8.97B
- EPS (TTM)
- $0.91
- PE Ratio
- 52.86
- PEG Ratio
- 0.21
- Total Revenue (TTM)
- $1.56B
- Gross Profit (TTM)
- $1.02B
- EBITDA (TTM)
- $249.70M
- Year Range
- $25.17 - $48.32
- Target Price
- $44.00
- ROA (TTM)
- 3.59%
- ROE (TTM)
- 8.72%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ALKS Performance Chart
Alkermes plc (ALKS) is up 71.8% since the beginning of the year. At $48 per share, ALKS is trading just below its 52-week high of $48. Investors who bought $1,000 worth of ALKS shares 5 years ago would now be looking at an investment worth $1,960.
Loading charts...
Returns By Period
Alkermes plc (ALKS) has returned 71.80% so far this year and 64.29% over the past 12 months. Over the last ten years, ALKS has returned 1.29% per year, falling short of the S&P 500 Index benchmark, which averaged 13.71% annually.
Alkermes plc
- 1D
- 4.45%
- 1M
- 30.62%
- YTD
- 71.80%
- 6M
- 68.73%
- 1Y
- 64.29%
- 3Y*
- 12.97%
- 5Y*
- 14.41%
- 10Y*
- 1.29%
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
ALKS Monthly Returns History
Based on dividend-adjusted daily data since Jul 16, 1991, ALKS's average daily return is +0.10%, while the average monthly return is +2.34%. At this rate, an investment would double in approximately 2.5 years.
Historically, 52% of months were positive and 48% were negative. The best month was Feb 2000 with a return of +189.4%, while the worst month was Jul 2002 at -71.5%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 7 months.
On a daily basis, ALKS closed higher 47% of trading days. The best single day was Jul 27, 1995 with a return of +34.1%, while the worst single day was Jul 1, 2002 at -67.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 21.12% | -11.18% | 17.48% | -4.67% | 25.16% | 13.94% | 71.80% | ||||||
| 2025 | 9.63% | 8.88% | -3.82% | -12.87% | 6.40% | -6.53% | -7.41% | 9.36% | 3.56% | 2.33% | -3.65% | -5.41% | -2.71% |
| 2024 | -2.49% | 9.76% | -8.82% | -9.35% | -4.65% | 2.99% | 13.36% | 4.14% | -1.62% | -8.18% | 12.92% | -0.90% | 3.68% |
| 2023 | 9.61% | -6.63% | 5.42% | 1.28% | 1.33% | 8.19% | -6.45% | -0.31% | -4.04% | -13.64% | -0.21% | 14.91% | 6.16% |
| 2022 | 9.63% | -2.51% | 5.83% | 9.65% | 3.47% | -0.20% | -14.07% | -7.54% | -5.66% | 1.66% | 9.16% | 5.45% | 12.34% |
| 2021 | 5.21% | -9.29% | -1.89% | 17.80% | 3.02% | 8.16% | 5.51% | 20.83% | -1.34% | -1.78% | -27.63% | 6.11% | 16.59% |
Benchmark Metrics
Alkermes plc has an annualized alpha of 15.66%, beta of 1.16, and R2 of 0.11 versus S&P 500 Index. Calculated based on daily prices since July 16, 1991.
- This stock participated in 132.42% of S&P 500 Index downside but only 126.17% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.11 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 15.66%
- Beta
- 1.16
- R²
- 0.11
- Upside Capture
- 126.17%
- Downside Capture
- 132.42%
Return for Risk
Risk / Return Rank
ALKS ranks 82 for risk / return — in the top 82% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Alkermes plc (ALKS) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ALKS | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.20 | ||
| Sortino ratioReturn per unit of downside risk | -0.11 | ||
| Omega ratioGain probability vs. loss probability | 1.29 | 1.32 | -0.03 |
| Calmar ratioReturn relative to maximum drawdown | 2.91 | 2.46 | +0.45 |
| Martin ratioReturn relative to average drawdown | 6.76 | 10.92 | -4.16 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Alkermes plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Alkermes plc was 96.14%, occurring on Jul 11, 2002. The portfolio has not yet recovered.
The current Alkermes plc drawdown is 50.97%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Dot-com crash2000–2002 | -96.14%Jul 2002 | 2y 4mo | — | 26y 4moMar 2000 - now |
1995 bear market1995 | -92.95%Jan 1995 | 2y 12mo | 2y 1mo | 5y 1moJan 1992 - Feb 1997 |
1997 bear market1997 | -64.67%Apr 1997 | 2mo 8d | 1y 9mo | 1y 11moFeb 1997 - Jan 1999 |
1991 bear market1991 | -44.58%Nov 1991 | 23d | 1mo 7d | 2moNov 1991 - Jan 1992 |
1999 bear market1999 | -28.50%May 1999 | 2mo 6d | 2mo 15d | 4mo 21dMar 1999 - Aug 1999 |
Drawdown Indicators
| ALKS | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.14% | -56.78% | -39.36% |
Max Drawdown (1Y)Largest decline over 1 year | -22.20% | -9.10% | -13.10% |
Max Drawdown (3Y)Largest decline over 3 years | -30.98% | -18.90% | -12.08% |
Max Drawdown (5Y)Largest decline over 5 years | -33.18% | -25.43% | -7.75% |
Max Drawdown (10Y)Largest decline over 10 years | -80.58% | -33.92% | -46.66% |
Current DrawdownCurrent decline from peak | -50.97% | -3.21% | -47.76% |
Average DrawdownAverage peak-to-trough decline | -67.22% | -10.71% | -56.51% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.54% | 2.04% | +7.50% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Alkermes plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Alkermes plc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for ALKS, comparing it with other companies in the Biotechnology industry. Currently, ALKS has a P/E ratio of 52.9. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for ALKS compared to other companies in the Biotechnology industry. ALKS currently has a PEG ratio of 0.2. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ALKS relative to other companies in the Biotechnology industry. Currently, ALKS has a P/S ratio of 5.2. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ALKS in comparison with other companies in the Biotechnology industry. Currently, ALKS has a P/B value of 4.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ALKS
Add Alkermes plc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ALKS